One of the hallmarks of ER+ breast cancer is its dependence on the phosphatidylinositol-3-kinase (PI3K) pathway, which is highlighted by the frequency of activating mutations in the gene PIK3CA (~40%), coding for the catalytic subunit of PI3K. Here, PIK3CA is linked to breast carcinoma.